Discover how molecular medicine is transforming the clinical practice of longevity, early disease detection and personalized medicine. This session highlights how the latest blood analysis enables the precise measurement and tracking of hundreds of protein and metabolite biomarkers. Learn how to take a truly preventative approach to healthcare by adopting molecular analysis in your practice.
Learning Objective #1: Understand how the analysis of protein and metabolite biomarkers can provide accurate, predictive insights into disease risk and progression.
Learning Objective #2: Uncover real world examples of using molecular medicine for early detection of chronic disease and cancers.
Learning Objective #3: Explore how to put molecular testing into practice and how you can differentiate your clinical practice.
Dr. Khaleghi has helped launch a series of successful health technology companies, with a focus on diagnostics. With degrees in medicine, bioengineering, computer science, and business, Dr. Khaleghi has served as Founding Chief Medical Officer, Co-Founder, or Board Member of approximately a dozen early stage health technology companies, with several exits.
Rob was the founding CEO and is the current President and CSO of Molecular You Corporation. Backed by his expertise in molecular diagnostics, molecularly targeted drug discovery and development, biochemistry and regulatory compliance, Rob Fraser drives the innovation behind Molecular You’s multi-biomarker analytics. He established a low cost method of measuring hundreds of biomarkers from a single blood sample, along with establishing a LLM model to incorporate the world’s leading scientific literature. Rob has also been involved in leading drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD. Rob received extensive training in the molecular mechanisms of endocrinology while completing his Ph.D. at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg, France. In addition to Rob’s scientific accomplishments, he has been involved in the raising of more than $37M in funding. Rob is also co-founder of GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind.